Neurofibroma, Plexiform
13
4
8
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
0.0%
0 terminated out of 13 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
100%
3 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 3 completed trials
Clinical Trials (13)
AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors
Observational Study to Evaluate the Effect and Safety of Selumetinib in Pediatric Patients With NF1-PNs
Real-World Treatment Study of Koselugo (Selumetinib)
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)
PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas
Medication Adherence in Children, Adolescents and Adults With Neurofibromatosis Type 1(NF1) on Clinical Treatment Trials
Treatment of NF1-related Plexiform Neurofibroma With Trametinib
Evaluation of Percutaneous Cryotherapy in the Treatment of Plexiform Neurofibromas and Unresectable Neurofibromas in Neurofibromatosis Type 1
Study of Imatinib in Children With Neurofibromatosis and Airway Tumors
Clinical Sequencing of Cancer and Tissue Repository: OncoGenomics
Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas
R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas